Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis.


Journal

The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378

Informations de publication

Date de publication:
02 2022
Historique:
revised: 16 09 2021
received: 04 06 2021
accepted: 21 09 2021
pubmed: 2 12 2021
medline: 19 2 2022
entrez: 1 12 2021
Statut: ppublish

Résumé

Clinical trials of biologics to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) have evaluated objective outcomes (e.g., University of Pennsylvania Smell Identification Test [UPSIT], nasal polyps score [NPS], and computed tomography Lund-Mackay score [CT-LMK]) and patient-reported symptoms (e.g., nasal congestion/obstruction [NC], loss of smell [LoS], and total symptom score [TSS]). We estimated anchor-based thresholds for clinically meaningful change in objective and patient-reported outcomes in patients with CRSwNP using data from LIBERTY NP SINUS-24 and SINUS-52 trials (NCT02912468; NCT02898454). Target patient-reported outcomes were NC, LoS, and TSS; target objective outcomes were UPSIT, NPS, and CT-LMK. Anchor measures were the 22-item sinonasal outcome test (SNOT-22) rhinologic symptoms domain and total score and rhinosinusitis visual analog scale (VAS). The appropriateness of each anchor measure was evaluated by reviewing correlations between change in anchor measures and target outcomes and descriptive scores on target outcomes by levels of change in the anchor measure. Established thresholds for anchor measures (3.8 points for SNOT-22 rhinologic symptoms, 8.9 points for SNOT-22 total, 1-category improvement for rhinosinusitis VAS) were used to estimate clinically meaningful score changes for each target outcome. Based on correlations between change in anchor measures and target outcomes, SNOT-22 rhinologic symptoms domain was deemed the most appropriate anchor measure. Using this anchor measure, thresholds for clinically meaningful within-patient change were NC: 1 point; LoS: 1 point; TSS: 3 points; UPSIT: 8 points; NPS: 1 point; and CT-LMK: 5 points. These thresholds support interpretation of efficacy results for target outcomes in CRSwNP trials. 2 Laryngoscope, 132:265-271, 2022.

Identifiants

pubmed: 34850966
doi: 10.1002/lary.29888
pmc: PMC9299621
doi:

Substances chimiques

Biological Products 0

Banques de données

ClinicalTrials.gov
['NCT02912468', 'NCT02898454']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

265-271

Informations de copyright

© 2021 Sanofi Genzyme and RTI Health Solutions. The Laryngoscope published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc.

Références

Int Forum Allergy Rhinol. 2017 Feb;7(2):128-134
pubmed: 28177596
Int Forum Allergy Rhinol. 2014 Dec;4(12):972-9
pubmed: 25323055
Rhinol Suppl. 2012 Mar;23:3 p preceding table of contents, 1-298
pubmed: 22764607
JAMA Otolaryngol Head Neck Surg. 2014 Aug;140(8):712-9
pubmed: 25074504
J Allergy Clin Immunol. 2017 Oct;140(4):1024-1031.e14
pubmed: 28687232
COPD. 2005 Mar;2(1):63-7
pubmed: 17136964
J Allergy Clin Immunol. 2006 Nov;118(5):1133-41
pubmed: 17088140
Laryngoscope. 2013 Jan;123(1):57-63
pubmed: 23280941
Clin Otolaryngol. 2009 Oct;34(5):447-54
pubmed: 19793277
Curr Allergy Asthma Rep. 2009 May;9(3):213-20
pubmed: 19348721
Allergy. 2013 Jan;68(1):1-7
pubmed: 23025484
J Allergy Clin Immunol. 2020 Sep;146(3):595-605
pubmed: 32524991
Clin Otolaryngol. 2018 Oct;43(5):1328-1334
pubmed: 29953729
Int Forum Allergy Rhinol. 2016 Apr;6(4):373-7
pubmed: 26678021
J Allergy Clin Immunol. 2011 Nov;128(5):989-95.e1-8
pubmed: 21958585
Rhinology. 2021 Apr 1;59(2):151-163
pubmed: 33459728
Rhinology. 2010 Sep;48(3):318-24
pubmed: 21038023
Curr Allergy Asthma Rep. 2010 May;10(3):194-201
pubmed: 20424997
PLoS One. 2015 Jul 01;10(7):e0127228
pubmed: 26132710
Am J Rhinol. 2007 Jan-Feb;21(1):19-26
pubmed: 17283555
Health Qual Life Outcomes. 2010 Aug 20;8:89
pubmed: 20727176
Lancet. 2019 Nov 2;394(10209):1638-1650
pubmed: 31543428
Rhinology. 2007 Jun;45(2):144-7
pubmed: 17708462
J Investig Allergol Clin Immunol. 2011;21 Suppl 1:1-58
pubmed: 21714471
Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):163-9
pubmed: 21476818
Curr Allergy Asthma Rep. 2011 Jun;11(3):247-52
pubmed: 21234819
J Allergy Clin Immunol. 2013 Jan;131(1):110-6.e1
pubmed: 23021878
J Clin Epidemiol. 2010 Aug;63(8):865-74
pubmed: 20172689
Int Forum Allergy Rhinol. 2017 Dec;7(12):1149-1155
pubmed: 29053911
Rhinology. 2019 Feb 1;57(1):32-42
pubmed: 29911211
J Allergy Clin Immunol Pract. 2019 Feb;7(2):589-596.e3
pubmed: 30193936
JAMA. 2016 Feb 2;315(5):469-79
pubmed: 26836729

Auteurs

Joseph K Han (JK)

Department of Otolaryngology & Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, Virginia, U.S.A.

Claus Bachert (C)

Upper Airways Research Laboratory and Department of Otorhinolaryngology, Ghent University, Ghent, Belgium.
Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, Sweden.
First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Stella E Lee (SE)

Division of Otolaryngology-Head & Neck Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, U.S.A.

Claire Hopkins (C)

Department of Otorhinolaryngology - Head and Neck Surgery, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Enrico Heffler (E)

Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Peter W Hellings (PW)

Upper Airways Research Laboratory and Department of Otorhinolaryngology, Ghent University, Ghent, Belgium.
Department of Otorhinolaryngology - Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.
Department of Otorhinolaryngology, Amsterdam University Medical Centres, Location AMC, Amsterdam, The Netherlands.

Anju T Peters (AT)

Allergy-Immunology Division and the Sinus and Allergy Center, Feinberg School of Medicine, Northwestern University, Evanston, Illinois, U.S.A.

Siddhesh Kamat (S)

Medical Affairs, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, U.S.A.

Diane Whalley (D)

Patient-Centered Outcome Assessment, RTI Health Solutions, Manchester, United Kingdom.

Shanshan Qin (S)

Patient-Centered Outcome Assessment, RTI Health Solutions, Research Triangle Park, North Carolina, U.S.A.

Lauren Nelson (L)

Patient-Centered Outcome Assessment, RTI Health Solutions, Research Triangle Park, North Carolina, U.S.A.

Shahid Siddiqui (S)

Medical Affairs, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, U.S.A.

Asif H Khan (AH)

Global Medical Affairs, Sanofi, Chilly-Mazarin, France.

Yongtao Li (Y)

Global Medical Affairs Respiratory, Sanofi, Bridgewater, New Jersey, U.S.A.

Leda P Mannent (LP)

Global Clinical Development, Sanofi, Chilly-Mazarin, France.

Isabelle Guillemin (I)

Patient Reported Outcomes, Sanofi, Lyon, France.

Chien-Chia Chuang (CC)

Health Economics and Value Assessment, Sanofi, Cambridge, Massachusetts, U.S.A.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH